Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

Experimental Diabetes Research
Thomas ForstAndreas Pfützner

Abstract

Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease accompanied by vascular dysfunction and a tremendous increase in cardiovascular mortality. Numerous adipose-tissue-derived factors and beta cell dysfunction contribute to the increased cardiovascular risk in patients with T2DM. Nowadays, numerous pharmacological interventions are available to lower blood glucose levels in patients with type 2 diabetes. Beside more or less comparable glucose lowering efficacy, some of them have shown limited or probably even unfavorable effects on the cardiovascular system and overall mortality. Recently, incretin-based therapies (GLP-1 receptor agonists and DPP-IV inhibitors) have been introduced in the treatment of T2DM. Beside the effects of GLP-1 on insulin secretion, glucagon secretion, and gastrointestinal motility, recent studies suggested a couple of direct cardiovascular effects of GLP-1-based therapies. The goal of this paper is to provide an overview about the current knowledge of direct GLP-1 effects on endothelial and vascular function and potential consequences on the cardiovascular outcome in patients with T2DM treated with GLP-1 receptor agonists or DPP-IV inhibitors.

References

Sep 1, 1979·Circulation·D B Zilversmit
Mar 1, 1989·Diabetes·G C WeirJ F Habener
Oct 14, 1988·Diabetes Research and Clinical Practice·T MatsuyamaS Tarui
Apr 1, 1993·Digestive Diseases and Sciences·A WettergrenJ J Holst
Dec 22, 1999·Endocrine Reviews·T J Kieffer, J F Habener
Feb 13, 2001·Endocrine Reviews·J Calles-Escandon, M Cipolla
Sep 19, 2001·Journal of Vascular Research·K MatherS Verma
Feb 6, 2002·Circulation·Subodh Verma, Todd J Anderson
Jun 12, 2002·Circulation·Henry C McGillUNKNOWN Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group
Oct 9, 2002·Current Medical Research and Opinion·Melanie J Davies
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Nobukazu IshizakaMinoru Yamakado
Dec 18, 2003·The American Journal of Medicine·Christopher J Lyon, Willa A Hsueh
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Jean-Pierre GutzwillerChristoph Beglinger
Sep 9, 2004·American Journal of Physiology. Endocrinology and Metabolism·Thomas NyströmAke Sjöholm
Jan 18, 2005·American Journal of Physiology. Heart and Circulatory Physiology·David C W LauSubodh Verma
Jun 1, 2005·Development, Growth & Differentiation·Chengtian Zhao, Anming Meng
Apr 14, 2006·Current Vascular Pharmacology·Suzanne M NichollMark G Davies
Jun 20, 2006·Journal of the American College of Cardiology·Allison B GoldfineMark A Creager
Jul 20, 2007·Annals of Internal Medicine·Shari BolenFrederick L Brancati
Aug 23, 2007·American Journal of Physiology. Endocrinology and Metabolism·Ananda BasuMichael J Joyner
Sep 1, 2007·BMJ : British Medical Journal·Dean T EurichJeffrey A Johnson

❮ Previous
Next ❯

Citations

Jan 12, 2013·Reviews in Endocrine & Metabolic Disorders·Cathryn M Kolka, Richard N Bergman
Jul 19, 2013·European Journal of Endocrinology·Marjan AlssemaJacqueline M Dekker
Dec 20, 2012·Current Cardiology Reports·Samar SinghPing H Wang
Jan 25, 2017·Diabetology & Metabolic Syndrome·Inka Miñambres, Antonio Pérez
Aug 18, 2017·European Journal of Clinical Investigation·Lana Kosi-TreboticAlexandra Kautzky-Willer
Apr 2, 2015·Basic & Clinical Pharmacology & Toxicology·Linnéa Eriksson, Thomas Nyström
Feb 14, 2013·Current Opinion in Endocrinology, Diabetes, and Obesity·Susan L Samson, Alan Garber
Jan 16, 2015·European Journal of Ophthalmology·Kristina BlaslovLea Duvnjak
Aug 26, 2016·Journal of Diabetes Science and Technology·Andreas PfütznerGunther Burgard
Aug 21, 2021·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Josh ReedVenkateswarlu Kanamarlapudi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.